Safety and Feasibility of Transcatheter Aortic Valve Replacement in COVID-19 Patients: A Case Series

Cardiovasc Revasc Med. 2021 Jul:28S:68-71. doi: 10.1016/j.carrev.2021.03.022. Epub 2021 Apr 6.

Abstract

In 2020, the coronavirus disease 2019 (COVID-19) pandemic has led to a decrease in interventional treatment for structural heart disease worldwide. In this context, the management of patients with symptomatic severe aortic stenosis (AS) or bioprosthetic valve dysfunction (BVD) represents a clinical challenge, as a delay in aortic valve replacement procedures may increase short-term morbidity and mortality. We report four cases of TAVR performed in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. All of them were discharged in good clinical conditions and no adverse events were reported at 30 days follow-up. Our experience suggests that in selected patients with mild SARS-CoV-2 infection and symptomatic native AS or BVD, TAVR has a favorable short-term outcome.

Keywords: Aortic stenosis; Bioprosthetic valve dysfunction; COVID-19; Heart failure; TAVI; TAVR.

Publication types

  • Case Reports

MeSH terms

  • Aortic Valve / diagnostic imaging
  • Aortic Valve / surgery
  • Aortic Valve Stenosis* / diagnostic imaging
  • Aortic Valve Stenosis* / surgery
  • COVID-19*
  • Feasibility Studies
  • Heart Valve Prosthesis*
  • Humans
  • Risk Factors
  • SARS-CoV-2
  • Transcatheter Aortic Valve Replacement* / adverse effects
  • Treatment Outcome